Mitochondrial Myopathy Protocol

NeurologicalModerate Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

Coenzyme Q10 (Ubiquinol)A

300-600mg daily (ubiquinol form)

Essential electron carrier in mitochondrial respiratory chain; directly supports ATP production

18 studies420 participants

Supporting Studies (1)

PMID: 25023515 - CoQ10 in primary mitochondrial diseases (2014)

Creatine MonohydrateA

5-10g daily

Buffers ATP via phosphocreatine system, compensating for impaired oxidative phosphorylation

↓Mitochondrial Cytopathies Symptoms↑Power Output↓Muscular Dystrophy Symptoms↑Neuromuscular Function↑Subjective Well-Being

12 studies280 participants

Supporting Studies (1)

PMID: 9040751 - Creatine in mitochondrial myopathies (1997)

Supporting Stack

Additional supplements for enhanced results

L-CarnitineB

2-3g daily

Transports fatty acids into mitochondria; often depleted in mitochondrial disorders

↑Exercise Capacity↓Heart Rate↑Lung Function↑Muscle Mass↑Oxygen Uptake

8 studies180 participants

Alpha-Lipoic AcidC

600mg daily

Mitochondrial antioxidant and cofactor for pyruvate dehydrogenase complex

4 studies80 participants

Riboflavin (Vitamin B2)B

100-400mg daily

Precursor to FAD, essential cofactor for Complex I and II of electron transport chain

6 studies120 participants

How This Protocol Works

Simple Explanation

Mitochondrial myopathies involve defective cellular energy production. The mitochondria—your cells' power plants—can't efficiently convert food into ATP energy. This protocol provides bypass mechanisms and essential cofactors.

•CoQ10 is the most important supplement—it's a direct component of the electron transport chain where energy is produced. Many patients have documented CoQ10 deficiency. High doses (300-600mg) can significantly improve muscle function.

•Creatine provides an alternative energy buffer. When mitochondria can't make enough ATP, the phosphocreatine system can donate phosphate groups to regenerate ATP quickly during muscle activity.

•L-Carnitine shuttles fatty acids into mitochondria for burning. Patients often have carnitine deficiency due to impaired mitochondrial function.

•Alpha-lipoic acid is both an antioxidant and a cofactor for energy-producing enzymes.

•Riboflavin is essential for Complexes I and II—some patients have dramatic responses to high-dose B2.

Expected timeline: Energy improvements may be noticed within 2-4 weeks. Maximum benefit typically requires 3-6 months. Response varies based on specific genetic defect.

Clinical Perspective

Mitochondrial myopathies result from mutations affecting oxidative phosphorylation (OXPHOS) complexes I-V. This protocol supports electron transport chain function and provides alternative energy pathways.

•CoQ10/Ubiquinol (A-grade): Functions as electron carrier between Complexes I/II and III. Primary CoQ10 deficiency is treatable; secondary deficiency common in other mitochondrial disorders. Ubiquinol form has superior bioavailability. Target dose: 10-30mg/kg/day in children, 300-600mg in adults (PMID: 25023515).

•Creatine (A-grade): Phosphocreatine shuttle provides rapid ATP regeneration independent of OXPHOS. Compensates for reduced oxidative capacity. Studies show improved strength and reduced fatigue in mitochondrial myopathy (PMID: 9040751).

•L-Carnitine (B-grade): Facilitates long-chain fatty acid transport via CPT system. Secondary carnitine deficiency common due to impaired β-oxidation. Dose: 50-100mg/kg/day.

•Alpha-lipoic acid (C-grade): Cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. Regenerates other antioxidants (glutathione, vitamins C/E).

•Riboflavin (B-grade): Precursor to FMN and FAD cofactors. Some Complex I deficiencies (ACAD9 mutations) are riboflavin-responsive.

Biomarkers: Lactate/pyruvate ratio, plasma amino acids, acylcarnitine profile, muscle biopsy OXPHOS enzyme activities.

Note: Response depends on specific mutation. Genetic testing guides prognosis and treatment expectations.

View All Protocols